https://www.selleckchem.com/products/ri-1.html
Rationale Lung cancer is the cancer with the highest incidence and mortality in China and worldwide. Among them, 85% are non-small cell lung cancer (NSCLC). No previous reports have been published to describe the clinical effect of the immune checkpoint inhibitor (ICI) sintilimab in NSCLC yet. Patient concerns We report a case of a 64-year-old woman with a 20-day history of chest pain with computed tomography scan showing a right lower lung mass. Diagnoses Squamous NSCLC was diagnosed by bronchoscopy. Interventions The patient was treated
إعجاب
علق
شارك
